ZVRA Zevra Therapeutics Forecast, Technical & Fundamental Analysis
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases... Show more
ZVRA is expected to report earnings to rise 2.36% to 14 cents per share on November 11
Q3'26
Est.
$0.14
Q2'26
Beat
by $0.03
Q1'26
Beat
by $0.53
Q4'25
Beat
by $0.14
Q3'25
Beat
by $0.02
The last earnings report on August 05 showed earnings per share of 14 cents, beating the estimate of 10 cents. With 275.04K shares outstanding, the current market capitalization sits at 663.91M.
A.I.dvisor indicates that over the last year, ZVRA has been loosely correlated with XERS. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ZVRA jumps, then XERS could also see price increases.
ZVRA in downward trend: price dove below 50-day moving average on July 24, 2026
ZVRA moved below its 50-day moving average on July 24, 2026 date and that indicates a change from an upward trend to a downward trend. In of 41 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 61 cases where ZVRA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The 10-day moving average for ZVRA crossed bearishly below the 50-day moving average on July 27, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZVRA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ZVRA's RSI Indicator exited the oversold zone, of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on August 07, 2026. You may want to consider a long position or call options on ZVRA as a result. In of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ZVRA just turned positive on August 06, 2026. Looking at past instances where ZVRA's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ZVRA advanced for three days, in of 280 cases, the price rose further within the following month. The odds of a continued upward trend are .
ZVRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 154 cases where ZVRA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ZVRA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.051) is normal, around the industry mean (20.281). P/E Ratio (12.022) is within average values for comparable stocks, (25.508). Projected Growth (PEG Ratio) (10.667) is also within normal values, averaging (3.845). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (4.900) is also within normal values, averaging (437.072).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZVRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
